Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Vandana Abramson

10 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCBRE1599

04/11/2016

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)

Treatment

VICCBRE1587

04/05/2016

An Open-Label, First -in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

Treatment

VICCBRE1557

03/11/2016

A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) with Paclitaxel in Patients with Triple Negative Metastatic Breast Cancer

Treatment

VICCBRE1552

02/02/2016

A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

Treatment

VICCBRE14101

12/04/2015

Phase I/II Study of BYL719 and Nab-Paclitaxel in Patients with Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Treatment

VICCBRE1543

09/30/2015

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of MPDL3280A (Anti−PD-L1 Antibody) in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple -Negative Breast Cancer

Treatment

VICCBRE1374

06/15/2015

Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination with Enzalutamide in Patients with Androgen Receptor Positive Triple Negative Metastatic Breast Cancer

Treatment

VICCBRE1430

08/12/2014

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Treatment

ECOGBRES1207

10/31/2013

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

Treatment

VICCBRE1320

08/16/2013

A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer